Forte Biosciences, Inc. (FBRX) |
| 35.09 1.19 (3.51%) 04-10 16:00 |
| Open: | 34.06 |
| High: | 35.3 |
| Low: | 32.46 |
| Volume: | 770,682 |
| Market Cap: | 487(M) |
| PE Ratio: | -7.45 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 41.81 |
| Resistance 1: | 35.80 |
| Pivot price: | 26.95 |
| Support 1: | 27.28 |
| Support 2: | 22.01 |
| 52w High: | 35.8 |
| 52w Low: | 4.9 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Financials
| EPS | -0.080 |
| Book Value | 4.720 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -58.1 |
| Return on Equity (ttm) | -110.7 |
Company news
Fri, 10 Apr 2026
Forte Biosciences: 2026 Is Major Inflection Point For FB102 (NASDAQ:FBRX) - Seeking Alpha
Fri, 10 Apr 2026
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts - Seeking Alpha
Thu, 09 Apr 2026
Forte Biosciences Boosts Market Position with $150M Public Offering - timothysykes.com
Thu, 09 Apr 2026
Forte Biosciences (NASDAQ: FBRX) registers 5.71M shares at $26.27 - Stock Titan
Thu, 09 Apr 2026
Brookline Capital Markets Cuts Forte Biosciences FY2026 Earnings Forecast - National Today
Thu, 09 Apr 2026
Forte Biosciences Prices $150 Million Stock Offering at $26.27; Underwriting Led by Guggenheim - TradingView — Track All Markets
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
